Clinically diagnosed PSP, including neuropathologically proven cases of PSP-type tauopathy, segregated into a third group, characterized by a decreased EV 3R/4R tau ratio and EV TDP-43 levels in the range of HC. The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.